Evidence map›Paper›PMID 23594534›Full record

ArticleThe Journal of investigative dermatology2013

Applications of nanoparticles for treating cutaneous infection.

Astrid M Westendorf

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Astrid M WestendorfInfection Immunology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. astrid.westendorf@uk-essen.de

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today, nanotechnology is finding applications in medicine. The unique physical and chemical properties of nanoparticles can overcome barriers and allow them to gain access to biological systems. Because of the increasing prevalence of microbial resistance to conventional therapies, the development of novel antimicrobials is imperative. Creating nanotechnology-based drug delivery systems with antibacterial and immunomodulatory activities may lead to novel treatments for cutaneous pathogens.

Indexed as

AlginatesAnti-Infective AgentsAnti-Inflammatory AgentsChitosanGlucuronic AcidHexuronic AcidsHumansNanoparticlesPropionibacterium acnesAlginatesAnti-Infective AgentsAnti-Inflammatory AgentsChitosanGlucuronic AcidHexuronic Acids

Identifiers

PMID23594534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.